Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Breast Cancer
The latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of ...
Read moreThe latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of ...
Read more© 2023 earth-news.info
..................................%%%...*...........................................$$$$$$$$$$$$$$$$$$$$--------------------.....